Dana-Farber Cancer Institute | Strategic Alliance Partners

December 10, 2023

Zanubrutinib continued to demonstrate improved progression-free survival benefit over ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, according to extended follow-up data from the phase 3 ALPINE trial.

December 10, 2023

Dana-Farber Cancer Institute is launching a first-of-its-kind, integrated clinic to increase early detection of precancerous conditions and to prevent cancer from arising in individuals at increased risk for the disease.

December 07, 2023

Administration of fam-trastuzumab deruxtecan significantly prolonged time-to-next treatment in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.

December 06, 2023

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 46th annual San Antonio Breast Cancer Symposium, December 5–9, 2023.

December 04, 2023

Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.

December 04, 2023

Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how this regulatory decision increases the importance of multidisciplinary collaboration.

December 04, 2023

Bradley A. McGregor, MD, expands on the feasibility and safety considerations addressed through the design and methodology of the DAD study; highlights dose-limiting toxicities and early responses seen with sacituzumab govitecan plus enfortumab vedotin in treatment-resistant mUC; and explains how these results support further investigation of other ADC doublets.

December 01, 2023

Erica L. Mayer, MD, MPH, discusses findings from research investigating CDK4/6 inhibitors in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

November 30, 2023

Drs Lunning and Jacobson discuss the characteristics of follicular lymphoma that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

November 30, 2023

Bradley J. Monk, MD, FACOG, FACS, and Paolo Tarantino, MD, discuss key data with B7-H4–directed antibody-drug conjugates across solid tumor types, the evolving role of antibody-drug conjugates in gynecologic cancers, and the importance of determining optimal sequencing with these agents in breast cancer.

November 29, 2023

Biagio Ricciuti, MD, discusses the need to improve the identification of patients with advanced non–small cell lung cancer that benefit most from immune checkpoint inhibition.

November 27, 2023

The Brain Tumour Charity awarded a Junior Fellows grants of £600,000 over four years - the first of its kind - to Dana-Farber Research Fellow Tyler Miller, MD, PhD.

November 21, 2023

Elizabeth Buchbinder, MD, discusses the investigation of treatment with nivolumab maintenance therapy in patients with melanoma who experienced severe immune-related adverse effects associated with combination therapy with nivolumab and ipilimumab.

November 21, 2023

Closing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.

November 21, 2023

Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.

November 16, 2023

The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall survival benefit compared with standard-of-care platinum-based chemotherapy in patients with recurrent, platinum-sensitive ovarian cancer.

November 16, 2023

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

November 14, 2023

Explore the pivotal role of the Moonshot Cancer Initiative and MCED Consortium in shaping the landscape of early cancer detection and screening, with a focus on innovative screening tools and legislative support.

November 14, 2023

Implementation challenges and the importance of equitable access in the future of multi-cancer early detection tests.

November 13, 2023

In a new paper in JCO Oncology Practice, bioethics researchers at Dana-Farber Cancer Institute call on medical societies, government leaders, clinicians, and researchers to work together to ensure AI-driven healthcare preserves patient autonomy and respects human dignity.